{'fraction_non_alphanumeric': 0.029347826086956522, 'fraction_numerical': 0.007608695652173913, 'mean_word_length': 5.822222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Plasminogen activator inhibitor‐1: a potential etiological role in livedoid vasculopathy

Livedoid vasculopathy (LV) is a chronic, recurrent skin disorder with unknown aetiology and pathogenesis that seriously affects the quality of life of people who suffer from it. Plasminogen activator inhibitor (PAI)‐1 is a primary inhibitory component of the endogenous fibrinolytic system in blood coagulation. PAI‐1 also plays a role in many other physiological processes and activities, including thrombosis, fibrosis, wound healing, angiogenesis, inflammation, cell migration, and adhesion. Enhanced expression and genotype polymorphism of PAI‐1 have been observed in LV patients. In this review, we summarise the known functions of PAI‐1 with emphasis on the roles that PAI‐1 probably plays in the pathogenesis of LV, thereby illustrating that PAI‐1 represents a potential LV biomarker and therapeutic target for treating LV.